R&D and Product Update

BIOVENTIX PLC

R&D AND PRODUCT UPDATE

7 Jan 2010

The Directors of Bioventix plc ("Bioventix" or "the Company") are pleased to
provide an update on the Company's research and development activities and the
current products in use by customers.

Research

During 2010, the main research focus was on the development of the antibody
panel to vitamin D (specifically 25-OH D2 and D3). As previously announced,
there was a technical breakthrough with the identification of a novel antibody
(vitD3.5H10) that recognises the above two forms of vitamin D with equal and
high affinity. The Directors believe that this will prove to be of value to
some Bioventix customers and anticipate that it will generate revenues in the
future.

In 2011, the research focus will move towards progesterone (a fertility
hormone) and benzodiazepines (class of drug that includes well known entities
such as temazepam, valium and rohypnol).

Development

During the period 2007-2009, antibodies to cortisol, hCG and troponin were made
and are now at various stages of R&D at Bioventix customers. Estimates appear
below of when the Directors believe that these projects may begin to produce
increased revenue for the Company. The activities required to enable these
anitibodies to reach commercialisation reside mainly with Bioventix's customers
and are therefore outside of the control of the Company.

Products

Final assay products based on Bioventix antibodies made a number of years ago
reached the market place in 2010. It is noteworthy that the estradiol,
testosterone and THC.cannabis antibodies were created in the period 2005-2007
and took from 3-5 years to reach the market. This lead-time is a natural
consequence of the R&D and regulatory steps that take place at Bioventix's
customers after samples have been delivered.

The table below summarises the Bioventix product portfolio at January 2011

Product pipeline

Project           Disease area       Bioventix R&D and   Launched in customer  
                                     date antibodies     diagnostic products   
                                     created             (or estimated launch  
                                                         data)                 
                                                                               
T3                Thyroid                    Approx 1990            Approx 1995
                                                                               
NT proBNP         Cardiac                           2004                   2007
                                                                               
Testosterone      Fertility                         2006                   2009
                                                                               
Estradiol         Fertility                         2005                   2010
                                                                               
THC (cannabis)    Drug testing                      2007                   2010
                                                                               
Cortisol          Adrenal/stress                    2008   Estimated after 2012
                                                                               
hCG               Pregnancy                         2007   Estimated after 2012
                                                                               
Vitamin D         General health                    2009   Estimated after 2012
                                                                               
Troponin          Cardiac                           2007   Estimated after 2013
                                                                               
Tacrolimus        Transplant drug                   2010   Estimated after 2013
                                                                               
Benzodiazepines   Drug testing       Current research in                      -
                                                    2011                       
                                                                               
Progesterone      Fertility          Current research in                      -
                                                    2011                       

The Directors of Bioventix plc accept responsibility for this announcement.

Bioventix plc

Peter Harrison, CEO

[phone]; [e-mail]

Keith, Bayley, Rogers & Co. Limited - PLUS Corporate Adviser

David Coffman

[phone]

ABOUT BIOVENTIX

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies (SMAs) with a primary focus on
their application in clinical diagnostics, such as in automated immunoassays
used in blood testing. The antibodies created at Bioventix are generated in
sheep and are of particular benefit where the target to be assayed is present
at low concentration and where conventional mouse monoclonal or polyclonal
antibodies derived from various species have failed to produce a suitable
reagent.

Bioventix was incorporated in 2003 following a management buyout of assets
(including technology and intellectual property) relating to the creation of
SMAs from KS Biomedix Limited. The management buyout was led by Peter Harrison
and principally funded by SpringHill Bioventures Sendirian Berhad, a venture
capital fund company registered and regulated by the Securities Commission in
Malaysia.

Since 2003, Bioventix has established a profitable commercial offering based on
its SMA technology and its shares became quoted on the PLUS-Market in London in
April 2010 (BVXP).